Schizophrenia Therapeutics: A Market Briefing

Description: Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality.

This briefing examines both current and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses the drugs currently in clinical trials, provides epidemiological information, and profiles the major competitors.

The information presented in this report is the result of primary and secondary research. Secondary research included data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. Primary research consisted of interviews and correspondence with company executives, clinicians, researchers and public health officials. The market forecasts are based on epidemiology, historical growth rates, probable product introductions, analyst expectations, and expert consensus.

Contents:

CHAPTER ONE: EXECUTIVE SUMMARY
Epidemiology
Management of Schizophrenia
Drugs in Development
Market Summary
World Market for Novel Antipsychotics
Scope and Methodology

CHAPTER TWO: INTRODUCTION

Schizophrenia
Symptoms
Economic Burden
Causes
Complications
Distorted Perceptions of Reality
Hallucinations and Illusions
Delusions
Incidence
Types

CHAPTER THREE: TREATMENT OPTIONS

Pharmacological Treatments
Relapse Management
Adherence

Non-Pharmacological Treatments
Psychosocial Treatments

CHAPTER FOUR: DRUGS IN CLINICAL TRIALS

Newer Treatment Approaches
Preclinical Agents
A320436
Dopamine D2 Partial Agonist Agent
ORG 25543
MEM 3454
Clera 120

Phase I Clinical Agents
LY 483518
SB 277011
MGS 0028
Muscarinic M1 Agonist Compound
SGS 518
Neboglamine

Phase II Clinical Agents
DAR 0100
Palindore
Reminertant
Lurasidone
Talnetant

Phase III Clinical Agents
Bifeprunox
Lonasen
Iloperidone

CHAPTER FIVE: MARKET FORECASTS

Opportunities and Drivers
World Market Breakdown
5H2 and D2 Antagonist Antipsychotic Agents
Atypical Antipsychotic Agents
5H1A and D2 Partial Agonist and D2 and D3 Antagonist Agents
Novel Antipsychotic Agents
Geographical Breakdown of Antipsychotic Agents

CHAPTER SIX: KEY PLAYERS

Astra Zeneca PLC
Abbott Laboratories
Johnson and Johnson
Novartis AG
Pfizer Inc.

LIST OF EXHIBITS
Exhibit 1: Schizophrenia Cases, Geographical Breakdown
Exhibit 2: Status of Key Late-Stage Antipsychotic Agents
Exhibit 4: World Market for Antipsychotics by Geographic Segment Summary 2004-2009
Exhibit 5: World Market for Antipsychotics by Drug Type Summary 2004-2009
Exhibit 7: Schizophrenia Cases, Geographical Breakdown
Exhibit 8: World Market for Antipsychotic Agents 2004-2009
Exhibit 9: Expected Launch Dates of Late Stage Antipsychotic Agents
Exhibit 10: World Market for Antipsychotics by Drug Type (5 H2 & D2 antagonists, atypical antipsychotics, 5 H1A & D2 partial agonist, D2 & D3 antagonists, and benzamides) 2004-2009
Exhibit 11: World Market for 5H2 and D2 Antagonist Segment
Exhibit 12: World Market for Atypical Antipsychotic Segment
Exhibit 13: World Market for 5H1A and D2 Partial Agonist Segment
Exhibit 14: World Market for D2 and D3 Antagonist Segment
Exhibit 16: World Market for Antipsychotics by Geographic Segment (U.S., Europe, Japan, ROW) 2004-2009
Ordering:

Order Online - http://www.researchandmarkets.com/reports/2860693/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Schizophrenia Therapeutics: A Market Briefing
Web Address: http://www.researchandmarkets.com/reports/2860693/
Office Code: SCD2AZ3E

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy:</td>
<td>USD 995 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 995</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1990</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name:  ____________________________  Last Name:  ____________________________
Email Address:  *
Job Title:  ____________________________
Organisation:  ____________________________
Address:  ____________________________
City:  ____________________________
Postal / Zip Code:  ____________________________
Country:  ____________________________
Phone Number:  ____________________________
Fax Number:  ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp